SequelSEC

NEPHROS INC NEPH

Surgical & Medical Instruments & Apparatus · CIK 0001196298 · Fiscal year ends 1231

Revenue
$18.79M
Fiscal year ended 2025-12-31
Operating income
$1.15M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

NEPHROS INC (NEPH) reported revenue of $18.79M and net income of $1.19M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEPHROS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NEPHROS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$18.79M$14.16M$14.24M$9.98M$10.22M$8.56M$10.33M$5.69M$3.81M$2.32M
Cost of revenue$7.16M$5.44M$5.83M$5.24M$4.58M$3.65M$4.25M$2.48M$1.52M$1.03M
Gross profit$11.62M$8.72M$8.40M$4.73M$5.63M$4.91M$6.08M$3.20M$2.29M$1.29M
Operating income$1.15M$6.00K-$1.59M-$4.34M-$3.25M-$4.28M-$3.16M-$3.02M-$2.23M-$2.87M
Net income$1.19M$74.00K-$1.58MUnavailable-$3.87M-$4.53M-$3.18M-$3.40M-$809.00K-$3.03M
Research & development$1.34M$906.00K$873.00K$1.26M$1.50M$2.76M$3.09M$1.54MUnavailableUnavailable
Weighted-average diluted sharesshares 10.97Mshares 10.60Mshares 10.39Mshares 10.30MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income$1.21M$89.00K-$1.58MUnavailableUnavailable-$4.53M-$3.40M-$3.42M-$2.60M-$3.03M
Income tax expense$12.00K$15.00K$0$0$0Unavailable-$225.00K-$93.00K-$1.79MUnavailable
Diluted EPS$0.11$0.01$-0.15$-0.73UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$9.00M$7.68M$8.91M$7.59M$7.20M$6.47M$6.12M$4.52M$3.30M$2.85M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

NEPHROS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$5.40M$3.76M$4.31M$3.63M$6.97M$8.25M$4.17MUnavailableUnavailableUnavailable
Total assets$13.64M$11.21M$11.86M$11.00M$17.65M$18.51M$11.63M$10.56M$4.98M$2.68M
Current assets$11.22M$8.30M$8.40M$8.26M$13.63M$15.15M$8.30M$8.17M$3.81M$1.26M
Total liabilities$3.44M$2.62M$3.50M$2.12M$2.90M$2.94M$3.94M$3.76M$3.03M$2.01M
Current liabilities$2.77M$1.56M$2.11M$1.41M$2.39M$1.32M$2.43M$2.65M$1.87M$895.00K
Total equity incl. NCI$10.20M$8.58M$8.36M$8.88M$14.75M$15.57M$7.69M$6.80M$1.95M$667.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$3.23M$2.62M$2.47M$3.15M$4.46M$5.30M$2.56M$1.86M$674.00K$479.00K
Accounts receivable$2.41M$1.78M$1.50M$1.29M$1.64M$1.36M$1.04M$1.36M$836.00K$388.00K
Goodwill$759.00K$759.00K$759.00K$759.00K$759.00K$759.00K$759.00K$748.00KUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$71.00K$343.00K$593.00K$824.00K$1.04MUnavailableUnavailable
Accounts payable$914.00K$649.00K$873.00K$740.00K$1.33M$423.00K$959.00K$836.00K$872.00K$585.00K

Cash flow

NEPHROS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$1.60M-$492.00K$827.00K-$3.23M-$1.42M-$6.90M-$2.28M-$3.66M-$77.00KUnavailable
Capital expendituresUnavailable$55.00K$75.00K$137.00K$36.00K$239.00K$14.00KUnavailableUnavailable$45.00K
Investing cash flow$0-$50.00K-$75.00K-$137.00K-$85.00K-$239.00K-$151.00K-$991.00KUnavailableUnavailable
Financing cash flow-$5.00K-$5.00K-$79.00K$34.00K$237.00K$11.22M$2.02M$7.05M$1.99MUnavailable
Net change in cash$1.64M-$547.00K$673.00K-$3.34M-$1.28M$4.08M-$415.00K$2.39MUnavailableUnavailable
Stock-based compensation$296.00K$153.00K$1.05M$982.00K$1.26M$779.00K$1.33M$985.00K$772.00K$551.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$140.00K$135.00K$214.00K$218.00K$192.00K$192.00K$186.00K$163.00K$218.00K$230.00K

Derived

NEPHROS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailable-$547.00K$752.00K-$3.37M-$1.45M-$7.14M-$2.29MUnavailableUnavailableUnavailable
Gross margin61.9%61.6%59.0%47.4%55.1%57.4%58.9%56.3%60.2%55.8%
Operating margin6.1%0.0%-11.2%-43.5%-31.8%-49.9%-30.5%-53.0%-58.4%-123.7%
FCF marginUnavailable-3.9%5.3%-33.8%-14.2%-83.4%-22.2%UnavailableUnavailableUnavailable
SBC / revenue1.6%1.1%7.4%9.8%12.3%9.1%12.9%17.3%20.3%23.8%
Current ratio4.06x5.31x3.98x5.85x5.70x11.44x3.42x3.08x2.04x1.41x
Revenue YoY growth32.7%-0.5%42.7%-2.4%19.3%-17.2%81.7%49.3%64.2%Unavailable
Net margin6.4%0.5%-11.1%UnavailableUnavailable-52.9%-30.8%-59.8%-21.2%-130.7%
R&D / revenue7.1%6.4%6.1%12.6%14.7%32.2%29.9%27.1%UnavailableUnavailable
CapEx / revenueUnavailable0.4%0.5%1.4%0.4%2.8%0.1%UnavailableUnavailable1.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate1.0%16.9%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NEPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.